Alopexx Inc. (ALPX)
NASDAQ: ALPX
· Real-Time Price · USD
0.00
null (null%)
At close: Apr 24, 2025, 3:47 PM
0.00% (1D)
| Bid | n/a |
| Market Cap | 0 |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | n/a |
| PE Ratio (ttm) | n/a |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 0 |
| Avg. Volume (20D) | 0 |
| Open | 0.00 |
| Previous Close | 0.00 |
| Day's Range | 0.00 - 0.00 |
| 52-Week Range | 0.00 - 0.00 |
| Beta | 0.00 |
About ALPX
Alopexx, Inc., a clinical stage biotechnology company, focusing on developing novel immune therapeutics for the prevention, treatment, and mitigation of bacterial, fungal, and parasitic infections. Its lead products include Vaccine AV0328, a synthetic poly N-acetyl glucosamine (PNAG) vaccine that has completed Phase I first-in-man trial for the treatment of streptococcus pneumoniae, meningococcal infections, Alzheimer's disease, and type 1 diabet...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 7, 2022
Employees NaN
Stock Exchange NASDAQ
Ticker Symbol ALPX
Website https://www.alopexx.com